201 related articles for article (PubMed ID: 24034310)
1. Reflections on market access for personalized medicine: recommendations for Europe.
Payne K; Annemans L
Value Health; 2013; 16(6 Suppl):S32-8. PubMed ID: 24034310
[TBL] [Abstract][Full Text] [Related]
2. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
Frueh FW
Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
[TBL] [Abstract][Full Text] [Related]
3. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
O'Donnell JC
Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
[TBL] [Abstract][Full Text] [Related]
4. Payers and the assessment of clinical utility for companion diagnostics.
Quinn B
Clin Pharmacol Ther; 2010 Dec; 88(6):751-4. PubMed ID: 21081944
[TBL] [Abstract][Full Text] [Related]
5. Personalized medicine policy challenges: measuring clinical utility at point of care.
van Rooij T; Wilson DM; Marsh S
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
[TBL] [Abstract][Full Text] [Related]
6. Financing of pediatric home health care. Committee on Child Health Financing, Section on Home Care, American Academy of Pediatrics.
Committee on Child Health Financing, Section on Home Care, American Academy of Pediatrics
Pediatrics; 2006 Aug; 118(2):834-8. PubMed ID: 16882849
[TBL] [Abstract][Full Text] [Related]
7. The faces of personalized medicine: a framework for understanding its meaning and scope.
Redekop WK; Mladsi D
Value Health; 2013; 16(6 Suppl):S4-9. PubMed ID: 24034312
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine and therapeutic decision-making in oncology: a commentary on key environmental issues.
Freeman RA
J Oncol Pharm Pract; 2011 Sep; 17(3):295-7. PubMed ID: 20551112
[No Abstract] [Full Text] [Related]
9. [Is it possible (and desirable) to administer a standard for an effective health policy for the European Union?].
Bruch M
Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(2):5-10. PubMed ID: 9534267
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
[TBL] [Abstract][Full Text] [Related]
11. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
12. Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries.
Govaerts L; Simoens S; Van Dyck W; Huys I
Value Health; 2020 May; 23(5):606-615. PubMed ID: 32389226
[TBL] [Abstract][Full Text] [Related]
13. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
Rocchi A; Menon D; Verma S; Miller E
Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
[TBL] [Abstract][Full Text] [Related]
14. A roadmap to parity in mental health financing: the case of Lebanon.
Yehia F; Nahas Z; Saleh S
J Ment Health Policy Econ; 2014 Sep; 17(3):131-41. PubMed ID: 25543116
[TBL] [Abstract][Full Text] [Related]
15. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
[TBL] [Abstract][Full Text] [Related]
16. Similarities and differences between five European drug reimbursement systems.
Franken M; le Polain M; Cleemput I; Koopmanschap M
Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
[TBL] [Abstract][Full Text] [Related]
17. Implementation of genomic medicine in a health care delivery system: a value proposition?
Wade JE; Ledbetter DH; Williams MS
Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):112-6. PubMed ID: 24619641
[TBL] [Abstract][Full Text] [Related]
18. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
19. Drug reimbursement decision-making in Thailand, China, and South Korea.
Ngorsuraches S; Meng W; Kim BY; Kulsomboon V
Value Health; 2012; 15(1 Suppl):S120-5. PubMed ID: 22265058
[TBL] [Abstract][Full Text] [Related]
20. Personalized medicine in Europe: not yet personal enough?
Di Paolo A; Sarkozy F; Ryll B; Siebert U
BMC Health Serv Res; 2017 Apr; 17(1):289. PubMed ID: 28424057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
